ARS Pharmaceuticals (SPRY) Cash from Operations (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Cash from Operations of 44946000.0 for Q1 2026, down 10.32% on a YoY basis from 50117410.15 in Q1 2025, and down 3.36% sequentially from 43485000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Cash from Operations (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Cash from Operations data on file, last reported at 44946000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 10.32% year-over-year to 44946000.0; the trailing twelve-month figure through Mar 2026 stood at 175070000.0 (down 754.67% YoY), and the FY2025 full-year result was 170866000.0, down 1361.19% from the prior year.
- Cash from Operations eased to 44946000.0 in Q1 2026, from 43485000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 42004000.0 in Q4 2024 to a low of 47047000.0 in Q3 2025.
- A 5-year average of 17741647.06 and a median of 14467000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations soared 341.33% in 2024 and tumbled 507.18% in 2025, its largest moves.
- Tracing SPRY's Cash from Operations over 5 years: stood at 20497000.0 in 2022, then climbed by 15.09% to 17405000.0 in 2023, then soared by 341.33% to 42004000.0 in 2024, then sank by 203.53% to 43485000.0 in 2025, then decreased by 3.36% to 44946000.0 in 2026.
- Business Quant data shows SPRY's Cash from Operations at 44946000.0 in Q1 2026, 43485000.0 in Q4 2025, and 47047000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -44.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.95 Mn |
| Mar 31, 2026 | -44.95 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Sep 30, 2025 | -47.05 Mn |
| Sep 30, 2025 | -47.05 Mn |
| Jun 30, 2025 | -39.59 Mn |
| Jun 30, 2025 | -39.59 Mn |
| Mar 31, 2025 | -40.74 Mn |
| Mar 31, 2025 | -40.74 Mn |
| Dec 31, 2024 | 42.00 Mn |
| Dec 31, 2024 | 42.00 Mn |
| Sep 30, 2024 | -14.47 Mn |
| Sep 30, 2024 | -14.47 Mn |
| Jun 30, 2024 | -7.28 Mn |
| Jun 30, 2024 | -7.28 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -17.41 Mn |
| Dec 31, 2023 | -17.41 Mn |